Brussels: On Jan 27, the European Union’s drug regulator gave the green light to Pfizer Inc’s (PFE.N) antiviral COVID-19 pill for treating high-risk patients. EU health commissioner Stella Kyriakides said the bloc was now making good progress on lining up treatments, which she described as ‘a second line of defense after vaccines’. “Paxlovid is the first oral antiviral for home use in our portfolio, and has the potential to make a real difference for persons at high risk of progression to severe COVID,” she said.
